The Motley Fool

Neil Woodford’s Latest Buys: Centrica PLC, Babcock International Group PLC, Paypoint plc, Drax Group Plc, Benchmark Holdings PLC And Midatech Pharma PLC

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Neil Woodford continues to build and shape the CF Woodford Equity Income fund he launched last June after calling time on his 26-year career with Invesco Perpetual.

During December, the master investor put more money into existing holdings Centrica (LSE: CNA), Babcock International (LSE: BAB), Paypoint (LSE: PAY), Drax (LSE: DRX) and Benchmark (LSE: BMK), and took a new position in Midatech Pharma.

5 Stocks For Trying To Build Wealth After 50

Markets around the world are reeling from the coronavirus pandemic… and with so many great companies trading at what look to be ‘discount-bin’ prices, now could be the time for savvy investors to snap up some potential bargains.

But whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be a daunting prospect during such unprecedented times.

Fortunately, The Motley Fool UK analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global upheaval…

We’re sharing the names in a special FREE investing report that you can download today. And if you’re 50 or over, we believe these stocks could be a great fit for any well-diversified portfolio.

Click here to claim your free copy now!

British Gas owner Centrica and engineering support services group Babcock are two of Woodford’s less visible FTSE 100 holdings.

Centrica’s shares are trading at multi-year lows, with investor sentiment hit by everything from unfavourable weather patterns during 2014 to political posturing and regulatory uncertainty surrounding the UK’s big energy firms. As a result, Centrica trades on a modest 12-month forecast P/E of 13, with a massive 6.4% dividend yield.

Babcock is also out-of-favour with the market. Its shares are at 52-week lows. Babcock doesn’t have much of a dividend yield and its P/E of 13.3 is a little higher than Centrica’s. But Woodford and his team consider both companies to be at “attractive valuation levels”.

The same goes for FTSE 250 firm Paypoint. This company, which is the UK’s leading consumer payments processor, through its retail networks, and internet and mobile channels, trades on a slightly growthier P/E of 14, but is a slightly growthier firm.

Fellow FTSE 250 constituent Drax is another holding that Woodford added to in December. The electricity generator’s shares took a bit of a dive on a surprise announcement from the Department of Energy & Climate Change that it would be consulting on biomass policy changes.

Woodford and his team acknowledge that the business is exposed to “considerable political risk currently”, but said: “Drax remains a strategically important asset in the UK electricity sector and we are confident in its ability to generate attractive returns for shareholders in the future”.

Woodford is best known for his big blue-chip holdings, but he has within the fund what might be called a sub-portfolio of dynamic smaller cap companies in the technology and medical sectors.

Woodford added to his holding in one of the larger of these companies: £270m animal healthcare technology firm Benchmark. He was happy to pay 85p a share when Benchmark did a placing to raise funds to acquire salmon breeding and genetics companies SalmoBreed and Stofnfiskur.

Finally, Woodford also participated in a 267p-a-share IPO of Midatech Pharma, a company which uses tiny particles of pure gold to treat cancer and other medical conditions. Woodford stumped enough cash to give him 20% of the £74m AIM-listed firm’s shares.

Is this little-known company the next ‘Monster’ IPO?

Right now, this ‘screaming BUY’ stock is trading at a steep discount from its IPO price, but it looks like the sky is the limit in the years ahead.

Because this North American company is the clear leader in its field which is estimated to be worth US$261 BILLION by 2025.

The Motley Fool UK analyst team has just published a comprehensive report that shows you exactly why we believe it has so much upside potential.

But I warn you, you’ll need to act quickly, given how fast this ‘Monster IPO’ is already moving.

Click here to see how you can get a copy of this report for yourself today

G A Chester has no position in any shares mentioned. The Motley Fool UK has recommended Centrica. The Motley Fool UK owns shares of PayPoint. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.